The Halftime Brief

Biology, labs, and the second half.

Plain-English research on peptides, hormones, and longevity — physician-reviewed.

Peptide 101: the most-asked beginner questions answered
Peptide 101

Peptide 101: the most-asked beginner questions answered

Peptide therapy FAQ for beginners. Plain-English answers on how peptides work, who prescribes them, and what to expect. Educational only.

3 minRead →
How peptides are different from hormones
Peptide 101

How peptides are different from hormones

Peptides vs hormones in plain English: most hormones are peptides, but the labels describe different things. Here is the clean way to tell them apart.

3 minRead →
How peptides are different from supplements
Peptide 101

How peptides are different from supplements

Peptides vs supplements in plain English: peptides are prescribed compounds prepared by a pharmacy. Supplements are not. Here is the clean way to tell them apart.

3 minRead →
Peptides vs hormones: the overlap and the distinction
Peptide 101

Peptides vs hormones: the overlap and the distinction

Every peptide is not a hormone, and every hormone is not a peptide. Here's a plain-English map of where the two overlap and where they diverge.

3 minRead →
The four peptide families: a practical classification for patients
Peptide 101

The four peptide families: a practical classification for patients

Peptide families explained in plain English: the four practical groups patients ask about — growth, healing, metabolic, and signaling. Not FDA-approved.

2 minRead →
Who asks about peptide injection technique and why
Injection FAQs

Who asks about peptide injection technique and why

Most people starting a peptide protocol have never given themselves an injection. Here is who asks about technique, what worries them, and what matters.

2 minRead →
Who uses 503A compounding pharmacies and why
Compounding

Who uses 503A compounding pharmacies and why

503A compounding pharmacies serve a specific population — patients who cannot use commercially available drugs. Here is who they serve and why the model exists.

2 minRead →
Who should get a comprehensive biomarker panel and when
Labs

Who should get a comprehensive biomarker panel and when

Not everyone needs a comprehensive biomarker panel — but some are overdue and do not know it. Here is who benefits most and when to start testing.

2 minRead →
Who asks about PT-141 and the questions behind the search
Sexual HealthDRIVE

Who asks about PT-141 and the questions behind the search

People searching for PT-141 are usually asking about low libido that has not responded to other approaches. Here is who asks and what they want to know.

2 minRead →
Who is at risk for sarcopenia and the signs to notice
LongevityPRESERVE

Who is at risk for sarcopenia and the signs to notice

Sarcopenia affects roughly 1 in 3 adults over 70, but muscle loss starts decades earlier. Here is who is most at risk and what signs to watch for.

2 minRead →
Who is drawn to longevity medicine and why
LongevityPRESERVE

Who is drawn to longevity medicine and why

Longevity medicine attracts a specific kind of person — not the worried well, but the proactively curious. Here is who seeks it out and why it matters.

2 minRead →
Who asks about tesamorelin and what they want to understand
Men's HealthPRIME

Who asks about tesamorelin and what they want to understand

People searching for tesamorelin are usually researching visceral fat and GHRH. Here is who asks, what they want to know, and what research shows.

2 minRead →

The second half deserves
a strategy.

Weekly on Thursdays. Plain-English research, physician-reviewed. No noise, no spam — unsubscribe in one click.